Navigation Links
Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results

Third Quarter Revenue Increased 70.9% to $9.2 Million

CHENGDU, China, May 15 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., (OTC Bulletin Board: TYNP), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced fiscal results for its third quarter ended March 31, 2008.

Revenue for the third quarter of 2008 increased 70.9% to approximately $9.2 million compared to approximately $5.4 million for the third quarter of 2007. The significant increase in revenues was due to strong demand of the Company's current product portfolio supported by enhanced marketing efforts and expansion of current sales channels.

Cost of goods sold for the third quarter was approximately $5.1 million, yielding a gross profit of $4.1 million and gross margins of 44.6%, compared to $2 million in gross profit and a gross margin of 37.5% during the third quarter of 2007. Thus, gross profits grew by 103.2% on a year-over-year basis. The increase in gross profit and improved margins were primarily attributable to the growth in revenue and our focus on high margin products in the Company's portfolio such as Ginkgo Mihuan Oral Liquid and Arpu Shuangxin Oral Liquid.

Operating expenses for the three months ended March 31, 2008 were $2.3 million, up 560.7% compared to the same period in 2007. Selling, general and administration expenses for the period increased to approximately $2.2 million from $0.33 million in the third quarter of 2007, which included a one-time expense of $0.4 million in public market listing expenses, in addition to increased investment in overall marketing including increased costs in advertisement, promotion and sales force related expenses. Research and development expenses were $89,372 in the three months ended March 31, 2008, versus $15,749.

Operating income for the third quarter of 2008 totaled approximately $1.9 million, a 10% increase from the $1.7 FLOWS FROM INVESTING ACTIVITIES

Acquisition of property and equipment (208,652) (54,939)

Construction in progress (67,820) --

Additions to intangibles (786,712) (865,844)

Net Cash Used by Investing

Activities (1,063,184) (920,783)


Proceeds from capital contribution 9,089,700 --

Proceeds from bank loans 2,674,873 --

Repayment of shareholder loans (143,967) (13)

Repayment of bank loans -- (40,386)

Net Cash Provided (Used) by

Financing Activities 11,620,606 (40,399)



EQUIVALENTS 12,999,668 (161,498)



million reported for the third quarter of 2007. Operating margins were 20.1% and 31.2% for the third quarter of 2008 and 2007, respectively. The decrease in the operating margin was due to increased spending on R&D and marketing to expand Tianyin's market presence, and the one-time expense of going public. Without going public and investing in the growth initiatives undertaken during the third quarter, margins would have increased.

For the third quarter of 2008, net income was approximately $1.3 million, a 10.9% decrease, compared to approximately $1.4 million for the third quarter of 2007. Fully diluted earnings per share were $0.05 compared to $0.11 for the third quarter of 2008 and 2007 respectively, based up on 24.5 million and 12.8 million shares. The decrease in net income was primarily due to the Company's one-time listing and marketing expenses incurred in the quarter as discussed above. Additionally, the Company had increased interest expense of $245,174 during the quarter versus $31,465 a year ago due to a financing in the third quarter and the recently established bank loan. The Company also increased its provision for income taxes from $225,663 to $337,132 during the current quarter, yielding an effective tax rate of 20.9% vs. 13.6%. The Company incurred approximately $800,000 in expenses, not including the increased marketing expenditures, during the third quarter of 2008, which were not present during the same period of 2007. The items included are the increased expenditures for R&D, interest, taxes, and going public expenses.

"We are very pleased to report another quarter of strong revenue growth. The success of our overall marketing strategy and focusing on high margin products enabled us to achieve a 70% increase in revenues for the third quarter of 2008. While the overall net income was impacted by several non-operating expenses , our focus on expanding our distribution channels has brought new distribution partners, has enabled us to gain incremental market share and is contributing to our overall growth," commented Dr. Guoqing Jiang, Chief Executive Officer of Tianyin. "In addition, our reputation as a premier pharmaceutical organization has attracted a number of experienced sales and marketing executives. We recently appointed Mr. Shenxing Yuan, an industry veteran who previously worked for two well-known Chinese pharmaceutical manufacturers, as the head of our first marketing division. His addition has enabled us to expand our second marketing division to over 400 salespersons, We would like to publicly welcome Mr. Yuan and I am confident that his promotion will not only help create a stronger marketing division, but lead to future growth for the overall organization. "

Nine Month Results

For the nine months ended March 31, 2008, revenues increased approximately 77.4% to $24.2 million compared to the same period in 2007. Gross profit was $10.2 million for the first nine months of 2008, representing an increase of 97.8% from the first nine months of 2007. Gross margins were 42.1% for the first nine months of 2008 compared to 37.8% for the same period in 2007.

Income from operations was $5.7 million for the first nine months of 2008, representing an increase of 41.6% over the first nine months of 2007. Operating margins were 23.4% for the first nine months of 2008 compared to 29.3% for the first nine months of 2007. Net income was approximately $4.4 million for the nine months ended March 31, 2008, an increase of approximately 32.6% from the same period in 2007. Fully diluted earnings per share were $0.27 compared to $0.26 for the first nine months of 2008 and 2007 respectively, based up on 16.7 million and 12.8 million shares.

Balance Sheet and Cash Flow

The Company had a current ratio of 6.4 to 1 and $13.6 million in cash and cash equivalents on March 31, 2008. The Company had Stockholders' equity of $31 million, with total assets of $34.4 million versus total liabilities of $3.4 million. For the first nine months of 2008, the Company generated $1.76 million in cash from operations versus $0.78 million for the same period in 2007.

Business Development

Tianyin's key products continue to gain market shares in China. Ginkgo Mihuan Oral Liquid, Tianyin's leading product and core prescription drug, obtained product entry into the formularies of over 30 Tier I and Tier II hospitals in China during the third quarter of 2008. Additionally, plans call for the Company to enter 150 more hospitals before December 31, 2008 which will result in further increase of total sales of Ginkgo Mihuan Oral Liquid.

Tianyin has successfully installed newly purchased equipment including a high speed tablet press machine, a high speed capsule filling machine, and a one-step granulator. The installation has increased the overall production capacity of solid dosage form by 15%. Tianyin signed manufacturing agreements with two major pharmaceutical manufactures, Sichuan Kofule Pharmaceutical Group and Sichuan Medco Pharmaceutical Group, which will further alleviate the current capacity deficiency and meet the rapidly increasing market demand of their products. Additionally, Sichuan local government has approved Tianyin's application for a new solid dosage production plant. Construction of the plant started in the end of April 2008.

Although China's strongest earthquake in 58 years hit Sichuan Province on May 12, the Company's production was not affected and no one from Tianyin was injured by the disaster.

"Supported by the Chinese government and increases in personal income which is providing the means to improve consumers' overall level of healthcare, the growth of the TCM industry remains robust. Backed by our experienced management team, enhanced sales and marketing efforts, diversified product portfolio and extensive pipeline, we believe we are well positioned to capitalize on the significant growth opportunity in the TCM industry," concluded Dr. Jiang.

Conference Call

The Company will host a conference call to discuss the 2008 third quarter financial results on Thursday, May 15, 2008 at 9:00 a.m. EDT. Interested participants should call 800-762-9058 within the United States, or US +1-480-629-9039 if calling internationally. The conference ID is 3879213. It is advisable to dial in approximately 5-10 minutes prior to 9:00 a.m. EDT. If you are unable to participate in the call at the scheduled time, a playback will be available on Thursday, May 15, 2008 at 12:00 p.m. EDT through Thursday, May 29, 2008 at 11:59 p.m. EDT. To listen to the playback, please call 800-406-7325 from within the United States, or US +1 303-590-3030 internationally. Please use pass code 3879213 for the replay.

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 34 modernized TCMs in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 51 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 523 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,187 employees. Tianyin achieved revenue of $20.4 million and net income of $3.95 million in FY2007 ending June 30, 2007.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please contact:

For the Company:

Allen Tang, Ph.D., MBA, Assistant to the CEO

Tel: +86-158-212-25642



HC International, Inc.

Alan Sheinwald

Tel: +1-914-669-0222



Tianyin Pharmaceutical Co. Inc.




March 31, 2008


Cash and cash equivalents $13,624,058

Accounts receivable, net of allowance of

$34,226 3,952,252

Inventory 2,607,587

Advance payments to vendors 1,812,132

Other receivables 52,690

Prepaid expenses and other current

assets 284,529

Total Current Assets 22,333,248



Total Assets $34,432,675



Accounts payable and accrued expenses $1,254,956

Short term bank loans 1,363,740

VAT taxes payable 237,651

Income tax payable 345,936

Other taxes payable 29,484

Other payables 160,265

Total Current Liabilities 3,392,032


Common stock, $0.001 par value,

50,000,000 shares authorized 14,587

14,587,200 shares issued and outstanding

Series A convertible preferred stock,

$0.001 par value, 9,515,625

shares issued and outstanding 9,516

Additional paid-in capital 17,934,459

Statutory reserve 1,189,912

Retained earnings 10,090,588

Accumulated other comprehensive income 1,801,581

Total Stockholders' Equity 31,040,643

Total Liabilities and

Stockholders' Equity $34,432,675

Tianyin Pharmaceutical Co. Inc.





Three Months Ended Nine Months Ended

March 31, March 31,

2008 2007 2008 2007

SALES $9,249,229 $5,412,969 $24,167,921 $13,622,991

COST OF GOODS SOLD 5,123,587 3,382,399 13,984,845 8,474,163

GROSS PROFIT 4,125,642 2,030,570 10,183,076 5,148,828



general and

administrative 2,180,161 327,773 4,380,702 1,129,549

Research and

development 89,372 15,749 150,930 29,129


Expenses 2,269,533 343,522 4,531,632 1,158,678

INCOME FROM 1,856,109 1,687,048 5,651,444 3,990,150




Other income -- 10 -- 1,442

Interest expense (245,174) (31,465) (311,536) (103,210)

Total Other (245,174) (31,455) (311,536) (101,768)

Income (Expenses)



INCOME TAX 1,610,935 1,655,593 5,339,908 3,888,382


INCOME TAX 337,132 225,663 893,779 536,599

NET INCOME 1,273,803 1,429,930 4,446,129 3,351,783







adjustment 780,932 63,644 1,355,898 170,267


INCOME $2,054,735 $1,493,574 $5,802,027 $3,522,050


SHARE $.09 $.11 $.33 $.26


PER SHARE $.05 $.11 $.27 $.26




BASIC 14,274,783 12,790,800 13,289,072 12,790,800

DILUTED 24,455,363 12,790,800 16,707,369 12,790,800

Tianyin Pharmaceutical Co. Inc.





2008 2007


Net Income $4,446,129 $3,351,783

Adjustments to reconcile net income to net cash

provided by operating activities:

Depreciation and amortization 273,060 293,572

Bad debt expense -- 19,434

Changes in current assets and current

liabilities: --

Accounts receivable (535,631) (2,195,180)

Inventory (550,711) (386,727)

Advance payments to vendors - 351,303

Other receivables 89,183 (107,288)

Prepaid expense and other current

assets (2,005,616) --

Accounts payable and accrued expenses (13,158) (401,089)

VAT taxes payable 9,280 48,797

Income tax payable 13,565 67,390

Other taxes payable 4,254 5,368

Other payables 26,753 (264,438)

Total Adjustments (2,689,021) (2,568,858)

Net Cash Provided by Operating

Activities 1,757,108 782,925


SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2008 Third Quarter Earnings Conference Call on Thursday, May 15, 2008 at 9:00 a.m. EDT
2. Tianyin Pharmaceutical to Present at Roth Third Annual China Discovery Tour in Beijing on May 20, 2008 at 12:40 p.m. Beijing Time
3. Viscorp, Inc. Announces Name Change to Tianyin Pharmaceutical Co Inc. and Begins Trading Under the Ticker OTC BB: TYNP
4. 11 Pharmaceutical Titans Headline Chemistry Outsourcing Conference Program in September in New Jersey
5. AMDL Subsidiary Donates Pharmaceuticals in China Earthquake Relief Effort
6. Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
7. Medsn to Become Indegene Pharmaceutical Solutions, Inc.: Change Signifies the Success of Its Innovative Global Services Model
8. Simcere Pharmaceutical Group Announces SFDA Approval of First-to-Market Generic Biapenem Injection Anxin
9. MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
10. Ferring Pharmaceuticals EUFLEXXA(R) to Serve as a Sponsor for the Babolat World Tennis Classic
11. Sunesis Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... On November 10, 2015, Bohrer ... Court of Connecticut on behalf of a home health care worker who provided companionship ... former home health care workers employed by Humana, Inc., Humana at Home, Inc., and ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Dental professionals who ... Cleveland, OH , are invited to attend Dr. Mark Iacobelli’s Advanced Implant Mentoring (AIM) ... in Cleveland, OH. , As the co-founders of Advanced Implant Mentoring (AIM), Dr. ...
(Date:11/25/2015)... ... , ... On November 23rd 2015 Cozy Products, a division of ... Cozy Products explains what this means for business moving forward. , The Tri Lite ... business model: to sell personal heaters that reduce energy consumption, are economical and keep ...
(Date:11/25/2015)... ... 2015 , ... Brillianteen, McGaw YMCA’s student-produced musical show, will ... Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. Auditions for this final production ... been a treasured tradition for numerous families in the Evanston community. Over the ...
(Date:11/25/2015)... ST. LOUIS, Missouri (PRWEB) , ... November 25, ... ... with Project HEAL, will provide scholarships for people struggling with eating disorders as ... Proceeds from the second annual event, held at Fox Run Golf Club ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Drug Monitoring (TDM) Market: Supplier Shares, ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Italian therapeutic drug monitoring market, including ...
Breaking Medicine Technology: